Omarigliptin (MK-3102)

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H335：Kann die Atemwege reizen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Omarigliptin (MK-3102) Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Merck earned its first global approval for omarigliptin in Japan in 2015, and phase III development is ongoing in other countries around the globe for this interesting small molecule DPP-4 inhibitor. Interestingly, while most DPP-4 inhibitors used to treat type 2 DM require daily administration, omarigliptin is a weekly treatment. The process-scale synthesis of omarigliptin has been nicely described in an October 2015 paper from the Merck process group.

• Beschreibung

  MK-3102 is a potent, reversible, and competitive inhibitor of dipeptidyl peptidase 4 (DPP-4; IC₅₀ = 1.6 nM; K_i = 0.8 nM). It is selective for DPP-4 over 168 proteases, ion channels, and enzymes with IC₅₀ values greater than 10 μM in all assays. MK-3102 significantly reduces blood glucose levels in a dose-dependent manner in vivo in rats. It also has a long half-life (11 and 22 hours in rat and dog, respectively) making it suitable for once weekly dosing. Clinical trials demonstrate that formulations containing MK-3102 reduce plasma glucose and HbA1c in patients with type 2 diabetes mellitus (T2DM).

• Verwenden

  Omarigliptin is a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor to be used as treatment for type 2 diabetes.

• Definition

  ChEBI: Omarigliptin is a pyrrolopyrazole.

• Synthese

  The synthesis began with the efficient condensation of pyrrolidinone 149 with dimethylformamide-dimethylacetal (DMF-DMA) to afford enaminoketone 150 in 88% yield. Subsequent condensation with hydrazine monohydrate gave tertiary alcohol 151 in 92% yield, and this step was followed by acid-promoted dehydration to afford fused pyrazole 152. An initial kinetic mesylation delivered a 1:5 ratio of 147:153, in favor of the undesired regioisomer. However, when the crude mixture was warmed to ambient temperature and treated with potassium tert-butoxide, thermodynamic equilibration provided the more stable N1-mesylate 147. This process furnished the desired regioisomer 147 in a 30:1 ratio and 84% yield over the two steps. Reaction monitoring by HPLC suggests that cleavage of the mesyl group of 153 results in anion formation on the adjacent nitrogen, which then allows for mesylation at the desired position.
  
  Ester 154 was subjected to a three-step sequence whereby alkylation with propargyl besylate followed by saponification with sodium hydroxide and Boc protection resulted in amide 155 in 75% yield over three steps. The Weinreb amide was then subjected to the Knochel ?°turbo Grignard?± reagent derived from 1-bromo-2,4-difluorobenzene to provide ketone 156 in 89% yield. An enantioselective transfer hydrogenation was carried out utilizing (R,R)-Ts- DENEB as the chiral induction reagent to afford intermediate 157 in excellent yield and enantio- and diastereoselectivity, which underwent ruthenium-mediated cyclization with the pendant alkyne to afford dihydropyran 158 in 86% yield. A two-step hydroboration/oxidation involving the endocyclic vinyl ether furnished 159 as a mixture of diastereomers in 89% yield, and this was followed by RuCl3/NaBO3-mediated oxidation to provide the lactone fragment 148 in 80% yield.
  
  Removal of the Boc group within 147 was effected upon treatment with TFA, affording intermediate 160, which was not isolated but instead exposed to ketone 148 under reductive amination conditions to afford diaminopyran 161 in excellent yield and diastereoselectivity (30:1 dr). Finally, Boc deprotection and crystallization from THF/heptanes furnished omarigliptin in an impressive 45% yield over its nine-step longest linear sequence.
  

• in vitro

  mk-3102 is a competitive, reversible inhibitor of dpp-4 and is more potent than sitagliptin. it is highly selective over all proteases tested, including qpp, fap, pep, dpp8, and dpp9. the compound has weak ion channel activity [1].

• in vivo

  mk-3102 was evaluated for its ability to improve glucose tolerance in lean mice. when orally administered 1 h prior to dextrose challenge in an oral glucose tolerance test, it significantly reduced blood glucose excursion in a dosedependent manner from 0.01 mg/kg to 0.3 mg/kg [1].

• Einzelnachweise

  [1] biftu t, sinha-roy r, chen p, qian x, feng d, kuethe jt, scapin g, gao yd, yan y, krueger d, bak a, eiermann g, he j, cox j, hicks j, lyons k, he h, salituro g, tong s, patel s, doss g, petrov a, wu j, xu ss, sewall c, zhang x, zhang b, thornberry na, weber ae. omarigliptin (mk-3102): a novel long-acting dpp-4 inhibitor for once-weekly treatment of type 2 diabetes. j med chem. 2014 apr 24;57(8):3205-12.

Omarigliptin (MK-3102) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(242)Suppliers